Lixte Biotech Hlds (LIXT)

$4.25 +0.05 (1.19%)
Market Cap 23.96M
Revenue (ttm) 0.00
Net Income (ttm) -3.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 69,200
Avg Vol 111,526
Day's Range N/A - N/A
Shares Out 5.70M
Stochastic %K 53%
Beta 0.88
Analysts Strong Buy
Price Target N/A

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab t...

Industry: Biotechnology
Sector: Healthcare
Phone: 631 830 7092
Fax: 631 982 5050
Website: lixte.com
Address:
680 East Colorado Boulevard, Suite 180, Pasadena, United States
Biggio
Biggio Nov. 27 at 10:01 PM
$LIXT Click here for the full snapshot: https://wallstreetnation.com/breakthrough-cancer-therapy LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)has just announced a game-changing acquisition that could transform the company from a $25 million market cap stock into something far more significant. The company has acquired Liora Technologies and its revolutionary LiGHT proton therapy platform… This platform is a breakthrough technology that has already had $300 million invested in its development…proven clinical validation at 230 MeV…and breakthrough economics that could finally make precision cancer treatment accessible to millions of patients worldwide.
0 · Reply
Yeueehehe
Yeueehehe Nov. 26 at 4:10 PM
$LIXT whoa
0 · Reply
Yeueehehe
Yeueehehe Nov. 25 at 5:13 PM
$LIXT lol
1 · Reply
UgoGreg
UgoGreg Nov. 25 at 3:39 PM
$LIXT https://youtu.be/jZyr3kwa9-4
0 · Reply
Yeueehehe
Yeueehehe Nov. 25 at 3:01 PM
$LIXT when delisting ????
0 · Reply
Yeueehehe
Yeueehehe Nov. 25 at 2:58 PM
$LIXT it’s coming soon
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 25 at 2:57 PM
$LIXT just slipped -8% lower to -17% (~125Kv) in the last few minutes, follow for more volatility.
0 · Reply
Boringholm
Boringholm Nov. 25 at 2:37 PM
$LIXT Only indication of what things could be worth in this deal is the mention of what they have invested in the technology "Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology"
0 · Reply
notreload_ai
notreload_ai Nov. 25 at 2:15 PM
$LIXT bought Liora Technologies to get the LiGHT System, a cutting-edge, high-precision proton therapy for cancer treatment. https://notreload.xyz/lixte-acquires-liora-gains-light-system-proton-therapy/
0 · Reply
ApeioriMomentum
ApeioriMomentum Nov. 25 at 1:56 PM
$LIXT Does anyone know how much they are paying for the acquisition? Wondering how much dilution we can expect. Or if theyll need to raise capital to complete the transaction. Thanks.
0 · Reply
Latest News on LIXT
LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

Dec 3, 2025, 11:00 AM EST - 1 day ago

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

Dec 3, 2025, 8:00 AM EST - 1 day ago

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

Nov 25, 2025, 8:30 AM EST - 9 days ago

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Oct 29, 2025, 8:00 AM EDT - 5 weeks ago

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Oct 16, 2025, 8:00 AM EDT - 7 weeks ago

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

Sep 16, 2025, 8:30 AM EDT - 2 months ago

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

Sep 15, 2025, 5:40 PM EDT - 2 months ago

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

Sep 10, 2025, 4:05 PM EDT - 3 months ago

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

Sep 5, 2025, 8:35 AM EDT - 3 months ago

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Sep 3, 2025, 8:00 AM EDT - 3 months ago

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

Aug 27, 2025, 8:15 AM EDT - 3 months ago

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Aug 25, 2025, 8:05 AM EDT - 3 months ago

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

Aug 19, 2025, 11:18 AM EDT - 3 months ago

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

LIXTE Biotechnology Holdings Provides Corporate Update

Aug 18, 2025, 8:00 AM EDT - 3 months ago

LIXTE Biotechnology Holdings Provides Corporate Update

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Aug 14, 2025, 9:06 PM EDT - 4 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

Aug 14, 2025, 8:05 AM EDT - 4 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

Aug 13, 2025, 8:49 AM EDT - 4 months ago

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

Aug 13, 2025, 7:30 AM EDT - 4 months ago

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Jul 16, 2025, 8:05 AM EDT - 5 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Jul 9, 2025, 5:15 PM EDT - 5 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 9, 2025, 8:05 AM EDT - 5 months ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 8, 2025, 2:57 PM EDT - 5 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 2, 2025, 4:05 PM EDT - 5 months ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 5 months ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 31, 2025, 8:30 AM EDT - 8 months ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Mar 27, 2025, 8:30 AM EDT - 9 months ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 25, 2025, 8:30 AM EST - 10 months ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 10:35 AM EST - 10 months ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 10 months ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Feb 10, 2025, 5:00 PM EST - 10 months ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Sep 4, 2024, 8:30 AM EDT - 1 year ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 26, 2024, 8:30 AM EDT - 1 year ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 19, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 15, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 10:50 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 11:00 AM EDT - 1 year ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 6, 2024, 8:30 AM EDT - 1 year ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Jun 3, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 20, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

May 8, 2024, 9:25 AM EDT - 1 year ago

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Mar 21, 2024, 8:30 AM EDT - 1 year ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Feb 27, 2024, 8:30 AM EST - 1 year ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Feb 26, 2024, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

Jan 29, 2024, 8:30 AM EST - 2 years ago

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Nov 13, 2023, 8:30 AM EST - 2 years ago

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Oct 9, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Sep 26, 2023, 8:30 AM EDT - 2 years ago

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Sep 20, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Jul 20, 2023, 4:05 PM EDT - 2 years ago

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Biggio
Biggio Nov. 27 at 10:01 PM
$LIXT Click here for the full snapshot: https://wallstreetnation.com/breakthrough-cancer-therapy LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)has just announced a game-changing acquisition that could transform the company from a $25 million market cap stock into something far more significant. The company has acquired Liora Technologies and its revolutionary LiGHT proton therapy platform… This platform is a breakthrough technology that has already had $300 million invested in its development…proven clinical validation at 230 MeV…and breakthrough economics that could finally make precision cancer treatment accessible to millions of patients worldwide.
0 · Reply
Yeueehehe
Yeueehehe Nov. 26 at 4:10 PM
$LIXT whoa
0 · Reply
Yeueehehe
Yeueehehe Nov. 25 at 5:13 PM
$LIXT lol
1 · Reply
UgoGreg
UgoGreg Nov. 25 at 3:39 PM
$LIXT https://youtu.be/jZyr3kwa9-4
0 · Reply
Yeueehehe
Yeueehehe Nov. 25 at 3:01 PM
$LIXT when delisting ????
0 · Reply
Yeueehehe
Yeueehehe Nov. 25 at 2:58 PM
$LIXT it’s coming soon
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 25 at 2:57 PM
$LIXT just slipped -8% lower to -17% (~125Kv) in the last few minutes, follow for more volatility.
0 · Reply
Boringholm
Boringholm Nov. 25 at 2:37 PM
$LIXT Only indication of what things could be worth in this deal is the mention of what they have invested in the technology "Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology"
0 · Reply
notreload_ai
notreload_ai Nov. 25 at 2:15 PM
$LIXT bought Liora Technologies to get the LiGHT System, a cutting-edge, high-precision proton therapy for cancer treatment. https://notreload.xyz/lixte-acquires-liora-gains-light-system-proton-therapy/
0 · Reply
ApeioriMomentum
ApeioriMomentum Nov. 25 at 1:56 PM
$LIXT Does anyone know how much they are paying for the acquisition? Wondering how much dilution we can expect. Or if theyll need to raise capital to complete the transaction. Thanks.
0 · Reply
IBOTTheDipAndTheDipWon
IBOTTheDipAndTheDipWon Nov. 25 at 1:54 PM
$LIXT My new favorite Interactive Brokers TWS feature: Multi-language news that cannot be adjusted to only display English! Bearish on everything.
0 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 25 at 1:43 PM
$LIXT This is a remarkable aquisition by LIXTE Biotechnology. "Liora’s LiGHT system is installed at STFC’s Daresbury Laboratory, which will be providing resources to develop a center of excellence for proton therapy treatment using the LiGHT system".
0 · Reply
Scoty_D
Scoty_D Nov. 25 at 1:32 PM
$LIXT Aweee snap! New aquisition. Is it a goody?
1 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 25 at 1:31 PM
$LIXT LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
0 · Reply
JD101
JD101 Nov. 13 at 12:43 AM
$LIXT data soon ?
0 · Reply
suspendFlow
suspendFlow Nov. 12 at 8:34 PM
$LIXT Yawn are we getting the results? Should happen in the next few weeks. Or just sell this turd for 500mil and be done with it
1 · Reply
MarilynEash846
MarilynEash846 Oct. 30 at 3:57 PM
$LIXT advancing treatment; AITX advancing growth — Reinharz shares AITX’s AI evolution, revenue growth, and investor-first strategy.
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 12:10 PM
$LIXT following closely
0 · Reply
Yeueehehe
Yeueehehe Oct. 27 at 10:35 PM
$LIXT waiting for 0.50
0 · Reply
DavidScott
DavidScott Oct. 20 at 2:44 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $BYND $LIXT $NMAX $NNDM $GME
0 · Reply
Biggio
Biggio Oct. 18 at 4:12 PM
$LIXT Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today outlined its fourth-quarter 2025 priorities and provided an update on its strategic business development and acquisition initiatives focused on oncology. “LIXTE is entering Q4 with clear operational goals and a disciplined approach to strategic expansion,” said Geordan Pursglove, Chairman and Chief Executive Officer. “We remain focused on advancing LB-100 in high-need cancer indications, while pursuing acquisitions of complementary oncology assets that could enhance our pipeline, accelerate development and create durable value for patients and shareholders.”
0 · Reply
AmySharp603
AmySharp603 Oct. 17 at 3:43 PM
$LIXT fighting disease, AITX fighting inefficiency — this momentum shows what operational execution really means.
0 · Reply